SCHEMBL4548468

SCHEMBL4548468

CCOC(=O)C(C)(C)Cc1nc(-c2ccc(OCc3ccc(OC)cc3)cn2)no1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.45
CYP2C9 P11712 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
CYP4F2 P78329 1/20 0.41
CYP4A11 Q02928 1/20 0.41
FFAR1 O14842 3/20 0.41
ALDH1A1 P00352 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
MAPT P10636 5/20 0.39
POLB P06746 1/20 0.39
TSHR P16473 3/20 0.39
LMNA P02545 1/20 0.39
ATM Q13315 1/20 0.39
NPY1R P25929 1/20 0.38
NPY2R P49146 1/20 0.38
PTGER4 P35408 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548470 0.88 NPC1 (0.47) CYP2C9HCAR2SMN1; SMN2NPC1RAB9A
SCHEMBL4548463 0.88 CYP4F2 (0.53) CYP2C9HCAR2SMN1; SMN2NPC1RAB9A
SCHEMBL4555562 0.84 HCAR2 (0.56) CYP2C9HCAR2SMN1; SMN2NPC1RAB9A
SCHEMBL10312560 0.83 CYP2C9 (0.46) CYP2C9HCAR2SMN1; SMN2NPC1RAB9A
SCHEMBL4548429 0.82 MAOB (0.46) MAOBHCAR2SMN1; SMN2NPC1RAB9A
SCHEMBL1568004 0.78 LMNA (0.65) SMN1; SMN2NPC1RAB9AFFAR1ALDH1A1
SCHEMBL4548464 0.78 HCAR2 (0.66) CYP2C9HCAR2SMN1; SMN2NPC1RAB9A
SCHEMBL4548476 0.77 LMNA (0.52) SMN1; SMN2NPC1RAB9AFFAR1ALDH1A1
SCHEMBL4548407 0.77 LMNA (0.52) CYP2C9HCAR2SMN1; SMN2NPC1RAB9A
SCHEMBL4548432 0.77 HCAR2 (0.49) HCAR2SMN1; SMN2NPC1RAB9AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
WO-2007002557-A1 NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, GPR119 MAOB 467/4885CYP2C9 1081/4885HCAR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.